Lonsurf’s efficacy was analyzed in a double-blind study, according to the report. Patients receiving the newly-approved drug lived an average of 7.1 months, while patients treated with a placebo lived an average of 5.3 months.
More articles on gastroenterology:
5 recent GI study findings to know
New drug shows potential in fighting C. diff: 4 notes
10 of the biggest GI/endoscopy stories in 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.